NMO Spectrum Evaluation (AQP4 with Reflex to MOG), CSF
Also known as: Transverse Myelitis Antibody, NMO Spectrum Disorder, NMO antibody, Aquaporin, Optic Neuritis Antibody
Use
NMO (neuromyelitis optica, Devic disease) is an immune‑mediated chronic inflammatory disease predominantly affecting the optic nerve and spinal cord, presenting with optic neuritis and myelitis. Limited forms—such as isolated optic neuritis, brainstem encephalitis, and longitudinally extensive transverse myelitis (LETM)—are referred to as NMO spectrum disorders (NMOSD). Detection of antibodies against AQP4 or MOG is associated with NMO and NMOSD; AQP4 is evaluated first, with reflex to MOG when appropriate, aiding diagnostic clarity.
Special Instructions
Reflex testing: If AQP4 Antibody, CSF is positive, AQP4 Antibody, Titer, CSF is performed at additional charge (CPT 86052). If AQP4 is negative, MOG Antibody, CBA is performed at additional charge (CPT 86362). If MOG Antibody, CBA is positive, MOG Antibody, Titer, CSF is performed at additional charge (CPT 86362).
Limitations
Not provided.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
1 mL
Container
sterile plastic screw‑cap vial
Causes for Rejection
Visible particulate matter
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 21 days |